CAMBRIDGE, MA, September 13, 2016 -- Aurora BioPharma, Inc. is pleased to announce that our CEO, Robert Brooks, will present at the 15th Annual BIO Investor Forum, a gathering attracting more than 900 private equity and public investors, research analysts, and industry executives participating in some 1,700 meetings and 175 public and venture stage company presentations. The event will take place October 18- 19 at the Westin St. Francis Hotel in San Francisco.
Aurora BioPharma is a biotechnology company, revolutionizing the way we will treat cancer in the future. After 50 years of surgery, radiation and chemotherapy, cancer rates are still expected to double in the next 15 years. Medicine has a new weapon, genetically reprogramming the immune system into an elite killer army. Already three companies involved in genetically engineered Chimeric Antigen Receptor (CAR) T therapy, have been awarded Breakthrough Therapy Designation by the FDA for showing up to 90% remissions or nearly a "cure" in leukemia and other liquid tumors. Aurora has shown in a human Phase I/II trial with Glioblastoma, the most lethal brain cancer, nearly double the survival of a $1 Billion drug without the side effects. Glioblastoma claimed the lives of Senator Ted Kennedy and Vice President Biden's son, and many others.
The BIO Investor Forum has continued to grow since its start in 2001 as a component of the larger BIO International Convention. The conference has expanded to include content rich programming, the SPARK showcase, company presentations, the "Buzz of BIO" contest and fireside chats.
Aurora BioPharma, Inc.
Tel: (617) 674-7718 - Fax: (617) 674-7701
SOURCE Aurora BioPharma, Inc.